Symptomatic treatment of urgency, increased micturition frequency &/or urgency incontinence as may occur in adult patients w/ overactive bladder (OAB) syndrome.
May increase BP. Measure BP at baseline & periodically especially in hypertensive patients. Patients w/ history of QT prolongation or who are taking medicinal products known to prolong the QT interval. Patients w/ bladder outlet obstruction & patients taking antimuscarinic medications for OAB. Not recommended in patients w/ ESRD (GFR <15 mL/min/1.73 m2 or requiring haemodialysis); severe renal impairment (GFR 15-29 mL/min/1.73 m2) concomitantly receiving strong CYP3A inhibitors; severe hepatic impairment (Child-Pugh class C); moderate hepatic impairment (Child-Pugh class B) concomitantly receiving strong CYP3A inhibitors. Not recommended during pregnancy & in women of childbearing potential not using contraception. Not to be administered during lactation. Childn <18 yr.
Sign Out
